StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) stock

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$69.06−5.12 (-6.90%)

Close on Nov 18, 2026Market cap $1.02BP/E –Yield –

Inhibrx Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Inhibrx Biosciences's operating income for the twelve months ending Sep 30, 2026 was -$125.73M. For fiscal 2025 it was -$135.03M. The highest annual figure on record is -$43.71M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$135.03M–
FY2024Dec 31, 2024-$331.45M–
FY2023Dec 31, 2023-$219.22M–
FY2022Dec 31, 2022-$129.12M–
FY2021Dec 31, 2021-$76.56M–
FY2020Dec 31, 2020-$67.44M–
FY2019Dec 31, 2019-$43.71M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$31.74M–
Q2 FY2026Jun 30, 2026-$32.15M–
Q1 FY2026Mar 31, 2026-$30.93M–
Q4 FY2025Dec 31, 2025-$30.92M–
Q3 FY2025Sep 30, 2025-$33.81M–
Q2 FY2025Jun 30, 2025-$27.39M–
Q1 FY2025Mar 31, 2025-$42.90M–
Q4 FY2024Dec 31, 2024-$49.93M–
Q3 FY2024Sep 30, 2024-$46.80M–
Q2 FY2024Jun 30, 2024-$160.90M–
Q1 FY2024Mar 31, 2024-$73.83M–
Q4 FY2023Dec 31, 2023-$88.29M–
Q3 FY2023Sep 30, 2023-$45.83M–
Q2 FY2023Jun 30, 2023-$41.34M–
Q1 FY2023Mar 31, 2023-$43.77M–
Q4 FY2022Dec 31, 2022-$35.50M–
Q3 FY2022Sep 30, 2022-$30.00M–
Q2 FY2022Jun 30, 2022-$34.60M–
Q1 FY2022Mar 31, 2022-$29.02M–
Q4 FY2021Dec 31, 2021-$19.40M–
Q3 FY2021Sep 30, 2021-$18.80M–
Q2 FY2021Jun 30, 2021-$19.80M–
Q1 FY2021Mar 31, 2021-$18.56M–
Q4 FY2020Dec 31, 2020-$17.11M–
Q3 FY2020Sep 30, 2020-$15.56M–
Q2 FY2020Jun 30, 2020-$17.17M–
Q1 FY2020Mar 31, 2020-$17.61M–
Q4 FY2019Dec 31, 2019-$16.45M–
Q3 FY2019Sep 30, 2019-$13.05M–

More Inhibrx Biosciences figures

See a number that looks wrong?